KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Change in Accured Expenses: 2016-2024

Historic Change in Accured Expenses for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to $235.1 million.

  • Amneal Pharmaceuticals' Change in Accured Expenses rose 48.87% to $69.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.0 million, marking a year-over-year decrease of 53.73%. This contributed to the annual value of $235.1 million for FY2024, which is 348.96% up from last year.
  • According to the latest figures from FY2024, Amneal Pharmaceuticals' Change in Accured Expenses is $235.1 million, which was up 348.96% from -$94.4 million recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' Change in Accured Expenses registered a high of $235.1 million during FY2024, and its lowest value of -$94.4 million during FY2023.
  • Over the past 3 years, Amneal Pharmaceuticals' median Change in Accured Expenses value was $109.6 million (recorded in 2022), while the average stood at $83.4 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first crashed by 14,410.10% in 2021, then soared by 349.40% in 2022.
  • Amneal Pharmaceuticals' Change in Accured Expenses (Yearly) stood at $307,000 in 2020, then slumped by 14,410.10% to -$43.9 million in 2021, then soared by 349.40% to $109.6 million in 2022, then plummeted by 186.20% to -$94.4 million in 2023, then spiked by 348.96% to $235.1 million in 2024.